US010478439B2

(12) **United States Patent**
Honigberg et al.

(10) **Patent No.: US 10,478,439 B2**
(45) **Date of Patent: *Nov. 19, 2019**

(54) **USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK)**

(71) Applicant: **Pharmacyclics LLC**, Sunnyvale, CA (US)

(72) Inventors: **Lee Honigberg**, San Francisco, CA (US); **David J. Loury**, Incline Village, NV (US)

(73) Assignee: **Pharmacyclics LLC**, Sunnyvale, CA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **15/965,114**

(22) Filed: **Apr. 27, 2018**

(65) **Prior Publication Data**

US 2018/0256581 A1 Sep. 13, 2018

Related U.S. Application Data

(63) Continuation of application No. 15/715,995, filed on Sep. 26, 2017, now Pat. No. 10,016,435, which is a (Continued)

(51) **Int. Cl.**

A61K 9/00	(2006.01)
A61K 9/06	(2006.01)
A61K 47/10	(2017.01)
A61K 47/12	(2006.01)
A61K 47/14	(2017.01)
A61K 47/20	(2006.01)
A61K 47/26	(2006.01)
A61K 47/36	(2006.01)
A61K 47/38	(2006.01)
A61K 9/48	(2006.01)
A61K 31/519	(2006.01)
A61K 31/195	(2006.01)
A61K 31/436	(2006.01)
A61K 31/454	(2006.01)
A61K 31/475	(2006.01)
A61K 31/573	(2006.01)
A61K 31/606	(2006.01)
A61K 31/675	(2006.01)
A61K 31/69	(2006.01)
A61K 31/704	(2006.01)

(Continued)

(52) **U.S. Cl.**

CPC ***A61K 31/519*** (2013.01); ***A61K 9/007*** (2013.01); ***A61K 9/0014*** (2013.01); ***A61K 9/0031*** (2013.01); ***A61K 9/0048*** (2013.01); ***A61K 9/0056*** (2013.01); ***A61K 9/06*** (2013.01); ***A61K 31/195*** (2013.01); ***A61K 31/337*** (2013.01); ***A61K 31/4184*** (2013.01); ***A61K 31/436*** (2013.01); ***A61K 31/437*** (2013.01); ***A61K 31/454*** (2013.01); ***A61K 31/475*** (2013.01); ***A61K 31/4745*** (2013.01); ***A61K 31/573*** (2013.01); ***A61K 31/606*** (2013.01); ***A61K 31/664*** (2013.01); ***A61K 31/675*** (2013.01); ***A61K 31/69*** (2013.01); ***A61K 31/704*** (2013.01); ***A61K 31/7032*** (2013.01); ***A61K 31/7076*** (2013.01); ***A61K 39/395*** (2013.01); ***A61K 39/3955*** (2013.01); ***A61K 39/39533*** (2013.01); ***A61K 45/06*** (2013.01); ***C07D 487/04*** (2013.01)

(58) **Field of Classification Search**

CPC .. A61K 31/195; A61K 31/436; A61K 31/454; A61K 31/475; A61K 31/519; A61K 31/573; A61K 31/606; A61K 31/675; A61K 31/69; A61K 31/704; A61K 31/7076; A61K 31/337; A61K 31/4184; A61K 31/437; A61K 31/4745; A61K 31/664; A61K 31/7032; A61K 39/395; A61K 39/39533; A61K 39/3955; A61K 45/06; A61K 2300/00; A61K 47/10; A61K 47/12; A61K 47/14; A61K 47/20; A61K 47/26; A61K 47/36; A61K 47/38; A61K 9/0014; A61K 9/0019; A61K 9/0031; A61K 9/0048; A61K 9/0056; A61K 9/007; A61K 9/0078; A61K 9/06; A61K 9/4866; C07D 487/04

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

3,547,119	A	12/1970	Farb
4,311,137	A	1/1982	Gerard

(Continued)

FOREIGN PATENT DOCUMENTS

CA	2663116	A1	4/2008
CA	2847852	A1	4/2008

(Continued)

OTHER PUBLICATIONS

Kimby (Acta Oncologica, 2001, 224-230). (Year: 2001).*

(Continued)

Primary Examiner — Umamaheswari Ramachandran
(74) *Attorney, Agent, or Firm* — Foley Hoag LLP

(57) **ABSTRACT**

Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.

17 Claims, 39 Drawing Sheets

Specification includes a Sequence Listing.